Q-omics provides the consensus-scored BZW1 profile across patient tissues and cancer cell-line models. BZW1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, BZW1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, BZW1 protein abundance shows 37,261 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where BZW1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BZW1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BZW1 survival associations across molecular data types. BZW1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BZW1 RNA expression–survival associations across cancer types. High BZW1 expression shows unfavorable associations in KIRP, ACC, CESC, PAAD, LUAD and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for BZW1 RNA expression.
This table summarizes BZW1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 13. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BZW1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BZW1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, STAD, BRCA and LUSC. The HNSC box plot shows higher BZW1 RNA expression in tumor versus normal tissue (log2 FC = +0.653, t-test p < 0.001).
This table shows molecular features associated with BZW1 in patient tissues and cancer cell lines. In patient samples, BZW1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BZW1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
